Open | - |
Close | - |
Volume / Avg. | 10.339K / 2.943M |
Day Range | - - - |
52 Wk Range | 2.230 - 6.890 |
Market Cap | $705.114M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 41 |
Short Interest | 20.37% |
Days to Cover | 9.13 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Allogene Therapeutics (NASDAQ: ALLO) through any online brokerage.
Other companies in Allogene Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Cogent Biosciences (NASDAQ:COGT), Fusion Pharmaceuticals (NASDAQ:FUSN), Pharming (NASDAQ:PHAR) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by HC Wainwright & Co. on Tuesday, March 19, 2024. The analyst firm set a price target for 10.00 expecting ALLO to rise to within 12 months (a possible 139.81% upside). 28 analyst firms have reported ratings in the last year.
The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $4.17 last updated Today at March 19, 2024 at 9:19 AM EDT.
There are no upcoming dividends for Allogene Therapeutics.
Allogene Therapeutics’s Q1 earnings are confirmed for Wednesday, May 1, 2024.
There is no upcoming split for Allogene Therapeutics.
Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.